Commons, Marty

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Study for the Treatment of Transfusional Iron Overload in Myelodysplastic Patients

Phase 4

Completed

Conditions: Iron Overload
Myelodysplastic Syndromes

Interventions: Drug: Deferasirox

First Posted Date: 2005-07-07

Last Posted Date: 2021-06-24

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 24

Registration Number: NCT00117507

Locations: 🇺🇸
Karmanos Cancer Center, Detroit, Michigan, United States
🇺🇸
Stanford University Medical Center, Stanford, California, United States
🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

Study of AEE788 in Patients With Recurrent/Relapse Glioblastoma Multiforme (GBM)

Phase 1

Completed

Conditions: Glioblastoma Multiforme

Interventions: Drug: AEE788

First Posted Date: 2005-06-29

Last Posted Date: 2015-11-10

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 64

Registration Number: NCT00116376

Locations: 🇺🇸
University of California at Los Angeles, Los Angeles, California, United States
🇺🇸
The Brain Tumor Center at Duke, Duke University Medical Center, Box 3624 DUMC, Trent Drive, Durham, North Carolina, United States
🇺🇸
University of Texas, MD Anderson Cancer Center, Houston, Texas, United States

and more 1 locations

Study of Deferasirox Relative to Subcutaneous Deferoxamine in Sickle Cell Disease Patients

Phase 2

Completed

Conditions: Sickle Cell Disease
Iron Overload
Hemolytic Anemia

Interventions: Drug: Deferasirox (ICL670)
Drug: Deferoxamine (DFO)

First Posted Date: 2005-05-11

Last Posted Date: 2011-05-26

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 212

Registration Number: NCT00110617

Locations: 🇺🇸
Pennsylvania Oncology/Hematology, Philadelphia, Pennsylvania, United States
🇺🇸
Children's Healthcare of Atlanta at Scottish Rite, Atlanta, Georgia, United States
🇺🇸
Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, United States

and more 55 locations

Efficacy and Safety of Vildagliptin Compared to Acarbose in Drug Naive Patients With Type 2 Diabetes

Phase 3

Completed

Conditions: Diabetes Mellitus, Type 2

First Posted Date: 2005-05-05

Last Posted Date: 2012-05-07

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 594

Registration Number: NCT00110240

Locations: 🇨🇭
Novartis Pharmaceuticals, Basel, Switzerland

Study of Deferasirox for Treatment of Transfusional Iron Overload in Myelodysplastic Patients

Phase 2

Completed

Conditions: Iron Overload
Myelodysplastic Syndrome

Interventions: Drug: Deferasirox

First Posted Date: 2005-05-05

Last Posted Date: 2021-08-16

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 176

Registration Number: NCT00110266

Locations: 🇺🇸
The Cleveland Clinic Foundation, Cleveland, Ohio, United States
🇺🇸
University of Kansas Medical Center, Kansas City, Kansas, United States
🇺🇸
Cedars-Sinai Medical Center, UCLA School of Medicine, Los Angeles, California, United States

and more 33 locations

A Study of Oral AMN107 in Adults With Chronic Myelogenous Leukemia (CML) or Other Hematologic Malignancies

Phase 1

Completed

Conditions: Chronic Myelogenous Leukemia
Acute Lymphoblastic Leukemia (Philadelphia Chromosome Positive)
Hypereosinophilic Syndrome
Systemic Mastocytosis

Interventions: Drug: Nilotinib

First Posted Date: 2005-05-03

Last Posted Date: 2021-06-29

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 507

Registration Number: NCT00109707

Locations: 🇺🇸
Sidney Kimmel Comprehensive Cancer Center/Johns Hopkins Med. Div.of Hematologic Malignancie, Baltimore, Maryland, United States
🇺🇸
Stanford University Medical Center, Stanford, California, United States
🇺🇸
University of Chicago Medical Center Dept. of U. of Chicago Hosp(3), Chicago, Illinois, United States

and more 22 locations

Efficacy, Safety and Tolerability of XBD173 in Patients With Generalized Anxiety Disorder

Phase 2

Completed

Conditions: Anxiety Disorders

First Posted Date: 2005-04-20

Last Posted Date: 2010-05-20

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 400

Registration Number: NCT00108836

Locations: 🇨🇦
Investigational Site, Sherbrooke, Quebec, Canada

Dose-finding Trial of HCD122 in Patients With Chronic Lymphocytic Leukemia (CLL) That is Relapsed or Non-responsive to Prior Fludaribine Therapy

Phase 1

Terminated

Conditions: Chronic Lymphocytic Leukemia

Interventions: Drug: HCD122

First Posted Date: 2005-04-15

Last Posted Date: 2012-10-01

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 26

Registration Number: NCT00108108

Locations: 🇺🇸
University of California San Diego StudyCoordinator:CHCD122A2101, La Jolla, California, United States
🇺🇸
St. Francis Cancer Research Foundation, Beech Grove, Indiana, United States
🇺🇸
The Sidney Kimmel Cancer Center at Johns Hopkins Hospital Div Of HematologicMalignancies, Baltimore, Maryland, United States

and more 2 locations

Study of Licarbazepine in the Treatment of Manic Episodes of Bipolar Disorder

Phase 3

Completed

Conditions: Bipolar Disorder

First Posted Date: 2005-04-12

Last Posted Date: 2017-03-22

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 453

Registration Number: NCT00107939

Locations: 🇺🇸
Investigational Site, West Allis, Wisconsin, United States
🇺🇸
Invetigational Site, Brooklyne, New York, United States

Study of Licarbazepine in the Treatment of Manic Episodes of Bipolar Disorder

Phase 3

Completed

Conditions: Bipolar Disorder

Interventions: Drug: Licarbazepine
Drug: Placebo

First Posted Date: 2005-04-12

Last Posted Date: 2017-03-22

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 343

Registration Number: NCT00107926

Locations: 🇻🇪
Novartis Investigational Site, Caracas, Venezuela
🇺🇸
Investigational Site, West Allis, Wisconsin, United States
🇨🇴
Guatemala, Pareira, Colombia

and more 1 locations

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy